A phase II study for the safety and efficacy of TAS-102 and Bevacizumab for patients with unresectable colorectal cancer considering Oxaliplatin to stop and go.
收藏NIAID Data Ecosystem2026-03-08 收录
下载链接：
https://www.omicsdi.org/dataset/ecrin-mdr-crc/2637794
下载链接
链接失效反馈官方服务：
资源简介：
Interventions: TAS-102+Bevacizumab
Primary outcome(s): PFS: Progression-free survival
Study Design: Single arm Non-randomized
创建时间：
2015-05-15
